Vistin Pharma ASA (LTS:0RAM) Total Stockholders Equity: kr350.3 Mil (As of Mar. 2026)


LTS:0RAM Vistin Pharma ASA LTS:0RAM
77 GF Score
Price kr20.70
GF Value kr25.62
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Vistin Pharma ASA Total Stockholders Equity?

Vistin Pharma ASA LTS:0RAM 77 Total Stockholders Equity is kr350.3 Mil as of Mar. 2026. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.62 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Vistin Pharma ASA's Total Stockholders Equity for the quarter that ended in Mar. 2026 was kr350.3 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Vistin Pharma ASA's Book Value per Share for the quarter that ended in Mar. 2026 was kr7.90. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Vistin Pharma ASA's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.00.

Vistin Pharma ASA  (LTS:0RAM) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Vistin Pharma ASA's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(350.306-0)/44.345
=7.90

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Vistin Pharma ASA's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 350.306
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistin Pharma ASA Total Stockholders Equity Related Terms

Vistin Pharma ASA Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Vistin Pharma ASA's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistin Pharma ASA Total Stockholders Equity Chart

Vistin Pharma ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 275.77 273.49 322.77 309.53 328.81

Vistin Pharma ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 331.23 294.27 312.80 328.81 350.31
LTS:0RAM
77GF Score
Vistin Pharma ASA LTS:0RAM
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of kr350.3 Mil mean?
Vistin Pharma ASA (LTS:0RAM) has a Total Stockholders Equity of kr350.3 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Vistin Pharma ASA and its competitors.
Is Vistin Pharma ASA's Total Stockholders Equity too high?
Vistin Pharma ASA's current Total Stockholders Equity is kr350.3 Mil. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Total Stockholders Equity compare to ZTS and UTHR?
Vistin Pharma ASA's Total Stockholders Equity of kr350.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Vistin Pharma ASA and its competitors. Vistin Pharma ASA's current Total Stockholders Equity is kr350.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.62, compared to a current price of kr20.70 — trading 19.2% below its estimated fair value. The current Total Stockholders Equity is kr350.3 Mil. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Total Stockholders Equity is kr350.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of kr20.70 is trading 19.2% below its estimated GF Value™ of kr25.62. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for LTS:0RAM:

  • Total Stockholders Equity: kr350.3 Mil
  • GF Value™: kr25.62 vs. price of kr20.70 (19.2% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score

Get the complete analysis for LTS:0RAM

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr20.70
Price
kr25.62
GF Value